Please wait while the formulary information is being retrieved.
MESNEX (MESNA)
- Prevention of chemotherapy-induced hemorrhagic cystitis
400 mg tablet
- 400 mg by oral route once daily
100 mg/mL intravenous solution
- Dosage information is not available
100 mg/mL intravenous solution
- Dosage information is not available
100 mg/mL intravenous solution
- Dosage information is not available
Prevention of chemotherapy-induced hemorrhagic cystitis
- Infuse 3 mg/kg by intravenous route 3 times per day
- Infuse 180 mg/m2 by intravenous route 3 times per day
- 400 mg by oral route once daily
- 400 mg by oral route once daily for 3 days
- Infuse 1,330 mg/m2 by intravenous route once daily
- Infuse 1,330 mg/m2 by intravenous route once daily for 3 days
- Infuse 1,250 mg/m2 by intravenous route once
- None
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- None
Severe
Moderate
- No disease contraindications
MESNEX (MESNA)
- Prevention of chemotherapy-induced hemorrhagic cystitis
- Granulocytopenic disorder
- Leukopenia
- Thrombocytopenic disorder
- Acute abdominal pain
- Alopecia
- Anemia
- Anorexia
- Constipation
- Diarrhea
- Drowsy
- Fatigue
- Fever
- General weakness
- Headache disorder
- Nausea
- Vomiting
More Frequent
Severe
Less Severe
- None
- Arthralgias
- Back pain
- Chest pain
- Chills
- Conjunctivitis
- Cough
- Dizziness
- Dysgeusia
- Dyspnea
- Dysuria
- Flu-like symptoms
- Hyperhidrosis
- Hypertension
- Hypesthesia
- Hypotension
- Injection site sequelae
- Lymphadenopathy
- Nasal congestion
- Paresthesia
- Photophobia
- Pleuritis
- Xerostomia
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Allergic dermatitis
- Anaphylaxis
- Angioedema
- Eosinophilia
- Hemoptysis
- Hepatitis
- Seizure disorder
- ST segment changes
- Stevens-johnson syndrome
- Toxic epidermal necrolysis
Less Severe
- Flushing
- Malaise
- Myalgias
- Pharyngitis
- Skin rash
- Tachycardia
- Tachypnea
- Urticaria
Contraindicated
None
Severe Precaution
Mesna (IV)
Contains benzyl alcohol. No safety and efficacy established.
- 1 Day – 364 Days
- Contains benzyl alcohol. No safety and efficacy established.
Management or Monitoring Precaution
Mesna (Oral)
No safety and efficacy established in children.
- 1 Day – 13 Years
- No safety and efficacy established in children.
Mesna
- Severity Level:
2
- Additional Notes: Animal data suggest no developmental tox; multidose vial contains benzyl alcohol
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Mesna
Insufficient data available.
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available. |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Formulary Reference Tool